Last reviewed 2026-05-22 · How we verify

Pemebit

Chonnam National University Hospital · Phase 2 active Small molecule ✓ Verified May 2026

Pemebit is a Small molecule drug developed by Chonnam National University Hospital. It is currently in Phase 2 development. Also known as: Pemetrexed.

Pemebit, also known as Pemetrexed, is being studied in combination with Cisplatin for the treatment of Adenocarcinoma and Lung Neoplasm. This combination chemotherapy is being investigated for its efficacy and safety in patients with post-operative Adenocarcinoma of the Lung.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Pemebit
Also known as	Pemetrexed
Sponsor	Chonnam National University Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pemebit CI brief — competitive landscape report
Pemebit updates RSS · CI watch RSS
Chonnam National University Hospital portfolio CI

Frequently asked questions about Pemebit

What is Pemebit?

Pemebit is a Small molecule drug developed by Chonnam National University Hospital.

Who makes Pemebit?

Pemebit is developed by Chonnam National University Hospital (see full Chonnam National University Hospital pipeline at /company/chonnam-national-university-hospital).

Is Pemebit also known as anything else?

Pemebit is also known as Pemetrexed.

What development phase is Pemebit in?

Pemebit is in Phase 2.

Manufacturer: Chonnam National University Hospital — full pipeline
Therapeutic area: All drugs in Other
Also known as: Pemetrexed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing